Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;2012:Cd006828.
2. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016;30:1079–85.
3. Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, Kumar L, Thibaud S, Richter J. POEMS syndrome: real world experience in diagnosis and systemic therapy-108 patients multicenter analysis. Clin Lymphoma Myeloma Leuk. 2022;22:297–304.
4. Pramanik R, Sharma A, Sharma A, Gogia A, Sahoo RK, Malik PS, et al. POEMS Syndrome: Indian experience from a tertiary-care institute. Clin Lymphoma Myeloma Leuk. 2019;19:e536–e544.
5. Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23:65–76.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献